EGFR and non-small cell lung carcinoma: In recent years, several phase III randomized trials have further reported that patients with NSCLC harboring EGFR mutations, such as exon 21 L858R point mutation and exon 19 deletion, have better progression‐free survival (PFS) when treated with an EGFR TKI.4, 5, 6, 7, 8, 9, 10, 11